Fig. 2From: A phase 3 randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of sarilumab in patients with giant cell arteritisPatient disposition. aOne patient completed the study period, including 24Â weeks follow-up. bIncludes patients who discontinued study treatment but completed scheduled study visits. COVID-19, coronavirus disease-2019; n, number of patients; PBO, placebo; SAR150/200, sarilumab 150/200Â mg; W, weekBack to article page